Trandolapril in left ventricular dysfunction after myocardial infarction: Focus on the trace study

Drugs of Today

Volumn 39, Issue 1, 2003, Pages 5-18

  Coca, A ^a   Rabasseda, X ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Prous Science ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO; TRANDOLAPRIL; TRANDOLAPRILAT; VERAPAMIL;

BLOOD PRESSURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DRUG HALF LIFE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIFE EXPECTANCY; LIPOPHILICITY; MORTALITY; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CLINICAL TRIALS; HUMANS; INDOLES; MYOCARDIAL INFARCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037232069     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.1.799429     Document Type: Review

References (42)

1. Le Pen, C., Lilliu, H., Keller, T, Fiessinger, S. The economics of TRACE: A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. Pharmacoeconomics 1998, 14: 49-58.
2. The TRACE study group. The TRAndolapril Cardiac Evaluation (TRACE) study: Rationale, design and baseline characteristics of the screened population. Am J Cardiol 1994, 73: 44C-50C.
3. Køber, L., Torp-Pedersen, C., Carlsen, J.E., Bagger, H., Eliasen, P., Lyngborg, K., Videbaek, J., Cole, D.S., Auclert, L., Pauly, N.C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333: 1670-6.
4. Okumura, Y., Nasa, Y., Sanbe, A., Toga, W., Takeo, S. Effects of long-term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure. J Card Fail 1996, 2: 301-10.
5. Toyoshima, H., Nasa, Y., Kohsaka, Y., Isayama, Y., Yamaguchi, F., Sanbe, A., Takeo, S. The effect of chronic treatment with trandolapril on cyclic AMP-and cyclic GMP-dependent relaxations in aortic segments of rats with chronic heart failure. Br J Pharmacol 1998, 123: 344-52.
6. Yoshida, H., Takahashi, M., Tanonaka, K., Maki, T., Nasa, Y., Takeo, S. Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure. Br J Pharmacol 2001, 134: 150-60.
7. Yamaguchi, F., Kawana, K., Tanonaka, K., Kamano, I., Igarashi, T., Gen, E., Fujimoto, Y., Maki, T., Sanbe, A., Nasa, Y., Takeo, S. Improvement of exercise capacity of rats with chronic heart failure by long-term treatment with trandolapril. Br J Pharmacol 1999, 126: 1585-92.
8. Yamaguchi, F., Sanbe, A., Takeo, S. Effects of long-term treatment with trandolapril on sarcoplasmic reticulum function of cardiac muscle in rats with chronic heart failure following myocardial infarction. Br J Pharmacol 1998, 123: 326-34.
9. Sanbe, A., Tsukada, J., Takeo, S. Effects of trandolapril on cardiac angiotensin I-converting enzyme activity in rats with chronic heart failure following myocardial infarction. Jpn Heart J 1995, 36: 451-63.
10. Fornes, P., Richer, C., Pussard, E., Heudes, D., Domergue, V., Giudicelli, J.F. Beneficial effects of trandolapril on experimentally induced congestive heart failure in rats. Am J Cardiol 1992, 70: 43-51D.
11. Richer, C., Mulder, P., Fornes, P., Domergue, V., Heudes, D., Giudicelli, J.F. Long-term treatment with trandolapril opposes cardiac remodeling and prolongs survival after myocardial infarction in rats. J Cardiovasc Pharmacol 1992, 20: 147-56.
12. Song, J.C. and White, C.M. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: An update. Clin Pharmacokinet 2002, 41: 207-24.
13. de Leeuw, P.W. Trandolapril: a clinical profile. Am J Hypertens 1995, 8: 68-70S.
14. Zannad, F. Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs 1993, 46 (Suppl. 2): 172-81.
15. Kober, L., Torp-Pedersen, C., Carlsen, J.E., Bagger, H., Eliasen, P., Lyngborg, K., Videbaek, J., Cole, D.S., Auclert, L., Pauly, N.C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670-6.
16. Torp-Pedersen, C., Kober, L., Carlsen, J. Angio-converting enzyme inhibition after myocardial infarction: The Trandolapril Cardiac Evaluation Study. Am Heart J 1996, 132 (1 Pt 2 Suppl.): 235-43.
17. Kober, L., Torp-Pedersen, C.T., Carlsen, J.E., Bagger, H., Eliasen, P., Lyngborg, K., Videbaek, J. The significance of trandolapril for mortality after AMI in patients with reduced left ventricular function. TRACE Study Group. Ugeskr Laeger 1997, 159: 1616-22.
18. Aliot, E. Trandolapril in patients with left ventricular insufficiency after myocardial infarction. Arch Mal Coeur Vaiss 1996, 89: 23-31.
19. Pedersen, O.D., Bagger, H., Kober, L., Torp-Pedersen, C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100: 376-80.
20. Gustafsson, F., Torp-Pedersen, C., Kober, L., Hildebrandt, P. Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. J Hypertens 1997, 15: 793-8.
21. Torp-Pedersen, C., Kober, L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 1999, 354: 9-12.
22. Gustafsson, I., Torp-Pedersen, C., Kober, L., Gustafsson, F., Hildebrandt, P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 1999, 34: 83-9.
23. Hansen, J.F., Hagerup, L., Sigurd, B., Pedersen, F., Mellemgaard, K., PedersenBjergaard, O., Mortensen, L.S. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group. Am J Cardiol 1997, 79: 738-41.
24. Hansen, J.F., Hagerup, L., Sigurd, B., Pedersen, F., Mellemgaard, K., Pedersen-Bjergaard, O. Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). J Hypertens (Suppl.) 1997, 15: S119-22.
25. Kownator, S., Dutrey-Dupagne, C., Vaur, L., Chevrier, J., Diesel, J., D'Hotel, R., Schaaf, R., Courvoisier A., Breton, C. Duration of action of trandolapril in mild to moderate hypertensive patients evaluated by ambulatory measurement of blood pressure. Therapie 1994, 4: 89-93.
26. Pauly, N.C, Safar, M.E., De Bruijn, J.H., Orofiamma, B.A., Pauly, N.C. Efficacy and tolerance of trandolapril (0.5-2 mg) administered for 4 weeks in patients with mild-to-moderate hypertension. Investigator Study Group. J Cardiovasc Pharmacol 1994, 23 (Suppl. 4): S60-4.
27. Kohlmann, J.O., Jardim, P.C., Oigman, W. Brazilian multicenter study on efficacy and tolerability of trandolapril in mild-to-moderate essential arterial hypertension. EMBATHE substudy with ambulatory blood pressure monitoring. Arq Bras Cardiol 1999, 72: 547-57.
28. Backhouse, C.I., Orofiamma, B., Pauly, N.C. Long-term therapy with trandolapril, a new non-sulfhydryl ACE inhibitor, in hypertension: A multicenter international trial. Investigator Study Group. J Cardiovasc Pharmacol 1994, 23 (Suppl. 4): S86-90.
29. Zannad, F., Vaur, L., Dutrey-Dupagne, C., Genes, N., Clerson, P. Antihypertensive effects of trandolapril and nitrendipine in the elderly: A controlled trial with special emphasis on time effect profiles. J Hum Hypertens 1996, 10: 51-5.
30. Evaluation of trandolapril alone or in combination with a calcium channel blocker in hypertensive patients over 60 years of age. Ann Cardiol Angeiol 1995, 44: 517-24.
31. Maarek, M., Bensaid, J. Efficacy and tolerability of trandolapril in overweight hypertensive patients. Ann Cardiol Angeiol 1996, 45: 343-51.
32. Galletti, F., Strazzullo, P., Capaldo, B., Carretta, R., Fabris, F., Ferrara, L.A., Glorioso, N., Semplicini, A., Mancini, M. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens 1999, 17: 439-45.
33. Poirier, L., Bourgeois, J., Lefebvre, J., Archambault, F., Lacourciere, Y. ACE Inhibitors as first-line treatment agents: A comparative study of trandolapril and enalapril on casual and ambulatory blood pressures. Am J Ther 1995, 2: 159-64.
34. Steiner, G. Pauly, N.C. Comparison of the efficacy and safety of trandolapril and nifedipine SR in mild-to-moderate hypertension. Investigator Study Group. J Cardiovasc Pharmacol 1994, 23 (Suppl. 4): S81-5.
35. Meyer, B.H., Pauly, N.C. Double-blind comparison of the efficacy and safety of trandolapril 2 mg and hydrochlorothiazide 25 mg in patients with mild-to-moderate essential hypertension. Investigator Study Group. J Cardiovasc Pharmacol 1994, 23 (Suppl. 4): S77-80.
36. Pauly, N.C., Safar, M.E. Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mild-to-moderate essential hypertension. Investigator Study Group. J Cardiovasc Pharmacol 1994, 23 (Suppl. 4): S73-6.
37. Bobrie, G., Dutrey-Dupagne, C., Vaur, L., Dubroca, I., Elkik, F., Chatellier, G., Menard, J. Demonstration of differences in the effect of 2 antihypertensive agents by self blood pressure measurement: Comparison of trandolapril and perindopril. Therapie 1997, 52: 187-93.
38. Takase, H., Sugiyama, M., Nakazawa, A., Sato, K., Ueda, R., Dohi, Y. Long-term effect of antihypertensive therapy with calcium antagonist or angiotensin converting enzyme inhibitor on serum nitrite/nitrate levels in human essential hypertension. Arzneimittelforschung 2000, 50: 530-4.
39. Guller, B., Hall, J., Reeves, R.L. Cardiac effects of trandolapril in hypertension. Am Heart J 1993, 125: 1536-41.
40. De Luca, N., Rosiello, G., Lamenza, F., Ricciardelli, B., Marchegiano, R., Volpe, M., Marelli, C., Trimarco, B. Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril. Am J Cardiol 1992, 70: 52-90.
41. Kakhnovskii, I.M., Fomina, I.G., Ostroumov, E.L. et al. Gopten (trandolapril) in the treatment of chronic heart failure in patients with ischemic heart disease. Ter Arkh 1998, 70: 29-33.
42. van der Ent, M., Remme, W.J., de Leeuw, P.W., Bartels, G. L. Renal hemodynamic effects in patients with moderate to severe heart failure during chronic treatment with trandolapril. Cardiovasc Drugs Ther 1998, 12: 395-403.